Lubahn Jordon G, Sagalowsky Arthur I, Rosenbaum David H, Dikmen Erkan, Bhojani Rehal A, Paul Michelle C, Dolmatch Bart L, Josephs Shellie C, Benaim Elie A, Levinson Barry S, Wait Michael A, Ring W Steves, DiMaio J Michael
Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, Tex 75390, USA.
J Thorac Cardiovasc Surg. 2006 Jun;131(6):1289-95. doi: 10.1016/j.jtcvs.2006.01.038.
Renal cell carcinomas often form venous thrombi that extend into the vena cava. Frequently, cardiovascular consultation is necessary for complete surgical excision. We sought to investigate the risk factors, surgical techniques, and outcomes of patients treated for renal cell carcinoma with venous extension.
We reviewed the records of 46 consecutive patients who underwent surgical management of renal cell carcinoma with venous extension between 1991 and 2005. Data on patient history, staging, surgical techniques, morbidity, and survival were analyzed.
There were 29 men and 17 women with a mean age of 60.2 +/- 12.0 years. Twenty-five (54%) procedures were completed with cardiovascular assistance. Nephrectomy was performed in 44 (96%) cases. Three (7%) patients underwent right heart venovenous bypass, and 2 (5%) patients underwent cardiopulmonary bypass with circulatory arrest. Fourteen (32%) patients had perioperative complications, including 1 (2%) perioperative death. Patients who required cardiovascular procedures (inferior vena cava clamping, right heart venovenous bypass, and cardiopulmonary bypass with circulatory arrest) had higher risks of perioperative complications (P < .02). The 1-, 2-, and 5-year overall survival rates were 78%, 69%, and 56%.
This large series demonstrates that aggressive treatment of renal cell carcinoma with venous thrombus provides favorable outcomes. Our 5-year survival is among the highest of recent reviews, and our perioperative morbidity and mortality rates are comparable with those of other series. Tumors that require cardiovascular procedures are associated with increased complications when compared with radical nephrectomy and thrombectomy alone. Nevertheless, this aggressive treatment approach offers encouraging patient survival.
肾细胞癌常形成延伸至腔静脉的静脉血栓。通常,为了完整切除肿瘤,需要心血管科会诊。我们试图研究肾细胞癌伴静脉延伸患者的危险因素、手术技术及治疗结果。
我们回顾了1991年至2005年间连续46例接受肾细胞癌伴静脉延伸手术治疗患者的记录。分析了患者病史、分期、手术技术、发病率及生存率等数据。
患者中男性29例,女性17例,平均年龄60.2±12.0岁。25例(54%)手术在心血管科协助下完成。44例(96%)患者接受了肾切除术。3例(7%)患者行右心静脉-静脉转流术,2例(5%)患者行体外循环并循环阻断。14例(32%)患者出现围手术期并发症,其中1例(2%)围手术期死亡。需要进行心血管手术(下腔静脉阻断、右心静脉-静脉转流术及体外循环并循环阻断)的患者围手术期并发症风险更高(P<0.02)。1年、2年和5年总生存率分别为78%、69%和56%。
该大型系列研究表明,积极治疗伴有静脉血栓的肾细胞癌可取得良好效果。我们的5年生存率在近期的综述中处于较高水平,围手术期发病率和死亡率与其他系列研究相当。与单纯根治性肾切除术和血栓切除术相比,需要进行心血管手术的肿瘤并发症增加。然而,这种积极的治疗方法为患者带来了令人鼓舞的生存前景。